Skip to main content

Table 5 Selected phase III trials that include MRD negativity rate as a primary clinical endpoint

From: Prognostic and predictive biomarker developments in multiple myeloma

Identifier

Regimen

Subjects

Sensitivity/method

Status

NCT03948035

Elo-KRd versus KRd prior to and after ASCT and maintenance with Elo-R versus R

576 NDMM eligible for ASCT

NR/MFC

Recruiting

NCT03652064

Dara-VRd followed by Dara-Rd versus VRd followed by Rd

395 NDMM patients for whom ASCT is not planned as initial therapy

10–5/NGS

Active, not recruiting

NCT03617731

Isa-RVd versus RVd for induction, ASCT and Isa-R versus R for maintenance therapy

662 NDMM eligible for ASCT

10–5/NGF

Active, not recruiting

NCT04751877

Isa-RVd versus Isa-Rd

270 NDMM non-eligible for ASCT

10–5/NGS

Recruiting

  1. Dara, Daratumumab; d, Dexamethasone; Elo, Elotuzumab; Isa, Isatuximab; K, Carfilzomib; R, Lenalidomide; V, Bortezomib; ASCT Autologous stem cell transplantation; NGF, next generation flow cytometry; NGS, next generation sequencing; MFC, multiparameter flow cytometry; NR, not reported; NDMM, newly diagnosed MM